ReviewMolecular biology reports2025
Targeting neurotrophic dysregulation in diabetic retinopathy: a novel therapeutic avenue.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gene-Agnostic Therapeutic Strategies for Inherited Retinal Diseases: Neuroprotection and Immunomodulation.Genes · 2026Review
- Neuroprotection in Diabetes Retinal Disease: An Unmet Medical Need.International journal of molecular sciences · 2026Review
- Neurodegeneration as an early driver and therapeutic target in diabetic retinopathy.International journal of ophthalmology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gradual retinal damage caused by chronic hyperglycemia is known as Diabetic retinopathy (DR), and it is the main cause of visual impairment and blindness in adults. The importance of neurotrophic factors in DR pathogenesis has been emphasized by recent studies. In diabetes, several naturally occurring proteins undergo substantial changes that impact neuronal survival, development, and differentiation. A number of neurotrophic factors, such as Brain-derived neurotrophic factor (BDNF), Nerve growth factor (NGF), Ciliary neurotrophic factor (CNTF), Glial cell line-derived neurotrophic factor (GDNF), Insulin-like Growth Factor-1 (IGF-1), fibroblast growth factor (FGF) play interdependent roles in DR, and this review offers a new prospective into these relationships. The processes for downregulating these neurotrophic factors were investigated, together with their altered expression patterns, action mechanisms, and therapeutic target potential, in this review. The crosstalk between neurotrophic factors and inflammatory pathways, oxidative stress, and vascular dysfunction in the diabetic retina is elucidated, offering insights into the complex neurovascular interplay in DR. Furthermore, emerging therapeutic strategies aimed at modulating neurotrophic factors to prevent or ameliorate retinal neurodegeneration are discussed. This comprehensive overview underscores the necessity for integrated approaches targeting neurotrophic support to develop effective interventions for diabetic retinopathy.
Indexed as
Identifiers
40488922What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.